Theravance Biopharma, Inc.
General ticker "TBPH" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $780.8M (TTM average)
Theravance Biopharma, Inc. follows the US Stock Market performance with the rate: 18.2%.
Estimated limits based on current volatility of 0.2%: low 17.03$, high 17.08$
Factors to consider:
- Total employees count: 90 (-7.2%) as of 2025
- US accounted for 100.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: YUPELRI acceptance decline, Viatris marketing obligations, Partner agreement termination, Market competition, Regulatory and compliance
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [12.57$, 21.63$]
- 2026-12-31 to 2027-12-31 estimated range: [12.17$, 21.13$]
Financial Metrics affecting the TBPH estimates:
- Positive: with PPE of 20.6 at the end of fiscal year the price was neutral
- Positive: Operating cash flow per share per price, % of 25.28 > 13.08
- Positive: -4.23 < Operating profit margin, % of -3.24
- Negative: negative Industry operating cash flow (median)
- Positive: Return on assets ratio (scaled to [-100,100]) of 17.90 > 6.06
- Negative: -0.75 < Inventory ratio change, % of 0
- Negative: Investing cash flow per share per price, % of -11.16 <= -4.49
- Positive: Interest expense per share per price, % of 0.26 <= 0.75
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term TBPH quotes
Long-term TBPH plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $57.42MM | $64.38MM | $107.46MM |
| Operating Expenses | $113.46MM | $111.33MM | $111.07MM |
| Operating Income | $-56.03MM | $-46.95MM | $-3.60MM |
| Non-Operating Income | $6.77MM | $2.33MM | $132.85MM |
| Interest Expense | $2.35MM | $2.55MM | $2.46MM |
| R&D Expense | $40.62MM | $37.64MM | $37.41MM |
| Income(Loss) | $-49.27MM | $-44.61MM | $129.25MM |
| Taxes | $5.92MM | $11.80MM | $23.35MM |
| Net Income(Loss)* | $-55.19MM | $-56.42MM | $105.89MM |
| Stockholders Equity | $213.00MM | $175.54MM | $296.72MM |
| Assets | $382.00MM | $354.16MM | $485.57MM |
| Operating Cash Flow | $-27.00MM | $-11.54MM | $238.54MM |
| Capital expenditure | $2.49MM | $0.33MM | $0.04MM |
| Investing Cash Flow | $-32.70MM | $12.28MM | $-105.28MM |
| Financing Cash Flow | $-198.93MM | $-2.50MM | $-3.25MM |
| Earnings Per Share** | $-1.00 | $-1.15 | $2.10 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.